<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890784</url>
  </required_header>
  <id_info>
    <org_study_id>DasaHIT</org_study_id>
    <nct_id>NCT02890784</nct_id>
  </id_info>
  <brief_title>Dasatinib Holiday for Improved Tolerability</brief_title>
  <acronym>DasaHIT</acronym>
  <official_title>Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve&#xD;
      disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase&#xD;
      Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dasatinib is indicated in Europe for:&#xD;
&#xD;
        -  Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+)&#xD;
           chronic myeloid leukemia (CML) in the chronic phase&#xD;
&#xD;
        -  Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy&#xD;
           including imatinib&#xD;
&#xD;
        -  Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast CML with resistance or&#xD;
           intolerance to prior therapy Compared to imatinib, dasatinib in CML achieves faster and&#xD;
           better responses. Dasatinib is known for its selected toxicities (fluid retention,&#xD;
           edema, pleural effusion, and hematological toxicity) requiring dose reductions or&#xD;
           treatment interruptions; these toxicities are more frequent in the first two years of&#xD;
           treatment. A randomized dose optimization trial for QD dosing vs. BID dosing has&#xD;
           demonstrated non-inferiority with regards to efficacy with an improved toxicity profile.&#xD;
           In a pilot study, analyzing patients with dasatinib toxicity, a fixed dasatinib weekend&#xD;
           holiday allowed safe toxicity management without impairing efficacy. Furthermore the&#xD;
           alternated schedule was also able to improve response parameters in patients that had&#xD;
           never achieved an acceptable response prior to the onset of dasatinib holiday dosing&#xD;
           schedule. The biological rationale for a holiday dosing schedule is that dasatinib has&#xD;
           shown an improved cell death of CML cells even after short exposure times; this improved&#xD;
           cell death exceeds the killing rate observed with imatinib in vitro. In summary, the&#xD;
           reported preclinical and clinical evidence indicates that efficacy seems to require&#xD;
           adequate dasatinib Cmax, while low Cmin (five half-lives between doses) does not impair&#xD;
           efficacy nor induces drug resistance. It is speculated that a weekend holiday, allowing&#xD;
           a better tolerability, would improve patients' drug adherence. The Investigators&#xD;
           hypothesize that a dasatinib holiday schedule (5x100mg+2x0mg weekly) compared to a&#xD;
           regular dose (7x100mg weekly) will reduce the rate of clinically significant toxicity&#xD;
           (e.g., fluid retention, hematological toxicity, musculoskeletal pain) by 20% observed&#xD;
           within the first two years of treatment. The Investigators also hypothesize that the&#xD;
           dasatinib holiday schedule is non-inferior to dasatinib regular dose in achieving the&#xD;
           European LeukemiaNet (ELN) recommended levels of response within the first 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative toxicity score</measure>
    <time_frame>month 24</time_frame>
    <description>The cumulative toxicity score after two years of dasatinib treatment. More specifically, toxicity will be assessed taking into account both the rate of grade 2-4 toxicities and the cumulative severity of adverse events of specific interest. The following AEs of specific interest will be used to compose the cumulative toxicity score:&#xD;
Pleural effusion&#xD;
Fluid retention, other (edema, pericardial effusion, pulmonary arterial hypertension, congestive heart failure, pulmonary edema)&#xD;
Hematological toxicity (neutropenia, thrombocytopenia, anemia)&#xD;
Others (Musculoskeletal pain, skin toxicity (rash), gastrointestinal toxicity (nausea, diarrhea, abdominal pain, vomiting)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of molecular Response</measure>
    <time_frame>month 24</time_frame>
    <description>The co-primary endpoint of the study is: rate of major molecular response (MMR) as assessed by BCR-ABL (IS [International Score] in %) -monitoring by 24 months to safeguard non-inferiority of the test cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>month 24</time_frame>
    <description>Quality of life assessment via Patient-Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular Response</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Rate of molecular response (MMR)as assessed by BCR-ABL (IS [International Score] in %) at 6 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>A. Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib (SPRYCEL®)</intervention_name>
    <description>Treatment optimization for patients with chronic myeloid leukemia (CML)</description>
    <arm_group_label>A. Standard arm</arm_group_label>
    <arm_group_label>B. Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph+&#xD;
             chromosome [t(9;22)(q34;q11)].&#xD;
&#xD;
          -  Ph negative cases or patients with variant translocations who are BCR-ABL positive in&#xD;
             multiplex PCR4 will be also considered eligible.&#xD;
&#xD;
          -  ECOG performance status ≤2.&#xD;
&#xD;
          -  Age ≥ 18 years old (no upper age limit is given)&#xD;
&#xD;
          -  Serum levels of potassium, magnesium and total calcium within the normal limits (≥LLN&#xD;
             [lower limit of normal] and ≤ULN [upper limit of normal]). Correction of electrolytes'&#xD;
             levels with supplements to meet enrolment criteria is allowed.&#xD;
&#xD;
          -  AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x ULN, except known Gilbert disease&#xD;
&#xD;
          -  Serum creatinine ≤2 x ULN&#xD;
&#xD;
          -  Written informed consent prior to any study procedures being performed.&#xD;
&#xD;
        For 1st-line patients:&#xD;
&#xD;
        • Pre-treatment with hydroxyurea up to 6 months and imatinib or dasatinib for duration of&#xD;
        up to 4 weeks is permitted.&#xD;
&#xD;
        For ≥ 2nd-line patients:&#xD;
&#xD;
        • Patients with treatment failure according to the 2013 ELN Recommendations criteria3 or&#xD;
        treatment intolerance as assessed by the investigator after prior treatment with TKIs other&#xD;
        than dasatinib (imatinib, nilotinib, bosutinib, ponatinib).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous allogeneic stem cell transplantation (AlloSCT)&#xD;
&#xD;
          -  Known impaired cardiac function, including any of the following:&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  History of or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmia&#xD;
&#xD;
               -  QTc &gt;450 msec on screening ECG&#xD;
&#xD;
               -  Myocardial infarction within 6 months prior to starting therapy&#xD;
&#xD;
          -  Other clinical significant heart disease (e.g. unstable angina pectoris, congestive&#xD;
             heart failure)&#xD;
&#xD;
          -  Acute or chronic viral hepatitis with moderate or severe hepatic impairment&#xD;
             (Child-Pugh scores &gt;6), even if controlled&#xD;
&#xD;
          -  Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled&#xD;
             infections, acute or chronic liver and renal disease) that could cause unacceptable&#xD;
             safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Impaired gastrointestinal function or disease that may alter the absorption of study&#xD;
             drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea,&#xD;
             malabsorption syndrome, small bowel resection or gastric by-pass surgery)&#xD;
&#xD;
          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450&#xD;
             isoenzyme CYP3A4&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who&#xD;
             have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding or women of reproductive potential not&#xD;
             employing an effective method of birth control. Women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 14 days prior to administration of&#xD;
             dasatinib. Post-menopausal women must be amenorrheic for at least 12 months in order&#xD;
             to be considered of non-childbearing potential. Male and female patients must agree to&#xD;
             employ an effective method of birth control throughout the study and for up to 3&#xD;
             months following discontinuation of study drug&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not&#xD;
             mandatory)&#xD;
&#xD;
          -  Active autoimmune disorder, including autoimmune hepatitis&#xD;
&#xD;
          -  Known serious hypersensitivity reactions to dasatinib&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hochhaus, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jena University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklinik der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Klausmann</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnkoBer</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel gGmbH</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Mohm/Prange-Krex</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios St. Johannes Klinik Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Karl-Leisner Klinikum</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Kooperation Harz</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ConMed GmbH</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Gemeinschaftspraxis Halberstadt</name>
      <address>
        <city>Halberstadt</city>
        <zip>38820</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle/S.</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios MVZ Onkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22417</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediProjekt GbR</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Kassel</city>
        <zip>34119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVo Institut für Versorgungsforschung</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Hämatologie und Onkologie</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum</name>
      <address>
        <city>Lebach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum UnterEms</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>München</city>
        <zip>80634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie/ Onkologie</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Neustadt Am Rübenberge</city>
        <zip>31535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Reutlingen GmbH</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologie-Onkologie Stolberg</name>
      <address>
        <city>Stolberg</city>
        <zip>52222</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinik Winnenden</name>
      <address>
        <city>Winnenden</city>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Andreas Hochhaus</investigator_full_name>
    <investigator_title>Director of the Clinic of Internal Medicine II</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

